Presentation to Extraordinary General Meeting
Released
Released
Announcement PDF
Company Presentation – EGM April 2024
RADIOPHARM THERANOSTICS LTD 2024
1
IMPORTANT NOTICE AND DISCLAIMER
The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required
by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did
not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional
investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own
risk.
Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf
of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No
responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any
communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated
persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation
or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly
disclaimed.
Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of
similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause
the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that
the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable
regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue
reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of
any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.
This presentation is not a prospectus or other disclosure document under the Corporations Act 2001 (Cth) and will not be lodged with the Australian Securities and
Investments Commission. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.
The distribution of this presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this presentation, you should observe
such restrictions as any non-compliance with these restrictions could contravene applicable securities laws (see the section captioned ‘International offer restrictions’). In
particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be,
registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration
requirements of the US Securities Act and applicable US state securities laws.
Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change.
RADIOPHARM THERANOSTICS LTD 2024
2
RAD IS AT THE CUTTING EDGE OF RADIOPHARMACEUTICALS,
A TRANSFORMATIVE MODALITY WITHIN CANCER
Differentiated Within Radiopharmaceuticals
• Clinical-stage company with deep pipeline of radiotherapy assets pursuing novel targets within radiotherapy, leveraging insights
from ADCs, using elegant targeting moieties such as nanobodies
– Targets include integrin αVβ6 , PDL-1, fatty acid synthase, HER2, B7H3 and TROP2
– Some being interrogated in indications where precedent molecules have not known to be focused or exploiting novel MoAs
Radiopharmaceuticals Expertise
• All team members with previous imaging and therapeutic radiopharmaceutical experience
• Extensive Scientific Advisory Board of accredited multinational researchers
Radiopharm Ventures, a Joint Venture with MD Anderson Cancer Center
• JV (private company) in-licensed from MDACC technologies for radiopharmaceuticals use
• First technology has been disclosed (B7H3-targeting molecule)
• Separate investment opportunity to enter JV with a significant position (currently RAD at 51%, MDACC at 49%)
In licensing Strategy & Intellectual Property
• Proprietary molecules designed to identify and target a broad range of malignancies, in solid tumors.
• Extensive patent portfolio for targets through 2040
RADIOPHARM THERANOSTICS LTD 2024
3
COMPANY PIPELINE
PROGRAM
RAD204
RAD301
RAD302
TARGET &
MOLECULE
PDL-1
(Nanobody)
Integrin
αVβ6
(Peptide)
INDICATION
Dx/Tx
ISOTOPE
NON-SMALL CELL
LUNG CANCER
Therapy
Lu177
Imaging
Ga68
Therapy
Lu177
PRECLINICAL
PHASE I
PHASE II
***
Phase 1** enrolling in Australia
FDA Orphan Drug Designation
***
PANCREATIC
CANCER
NOTES
Phase 1* enrolling in the US
Preclinical package to be completed by 2024
Phase 1 trial planned in early 2025
Phase 2a Phase 2b
RAD101
RAD102
RAD202
RV01
Additional
Preclinical
Programs
* NCT05799274
Fatty Acid
Synthase
Imaging
(Nanobody)
B7H3
BREAST /
GASTRIC CANCER
IND preparation for Phase 2b in US (n=30)
R&D stage
Therapy
I123
Therapy
Lu177
(mAb)
PROSTATE, LIVER
PANCREAS,
COLON
Therapy
KLK3 (mAb)
LRRC15 (mAb)
TROP2 (Nanobody)
Prostate
Osteosarcoma
TNBC/ NSCLC
Therapy
**ACTRN12623000959673
***
BRAIN METS
(Small Molecule)
HER 2
F18
Candidate selection ongoing at Imperial College of
London
Preclinical & CMC completed
Phase 1 trial planned in late 2024
From Joint Ventures MD Anderson-RAD
CMC production ongoing
Lu177
Preclinical package to be completed in late 2024
***Denotes clinical priorities.
Tb161
Tb161
Ac225
ADC targets.
Novel prostate targets.
RADIOPHARM THERANOSTICS LTD 2024
4
BETABART®: First and only B7-H3 radiopharmaceutical in development
BETABART®
Isoform-Selective Targeting of 4Ig-B7-H3
for PET Imaging and Beta-Radioligand Therapy
CANCER CELL
TARGET
B7H3
LINKER
TARGETING
MOLECULE
Betabart
RADIOACTIVE
ISOTOPE
177Lu
B7-H3 (CD276) IS AN EXQUISITE
TUMOR-SPECIFIC TARGET
BETABART HAS HIGH AFFINITY AND
SELECTIVITY FOR 4IG-B7-H3 ISOFORM
•
Conserved member of the B7 family
•
•
B7-H3 protein is highly expressed in many common
aggressive tumors and is not expressed or not
accessible in normal tissues
The 4Ig-B7-H3 isoform is the dominant isoform in
human cancers
•
•
B7-H3 expression on tumor-associated vascular and
“immune-suppressive” immune infiltrate
A soluble 2Ig-B7-H3 isoform circulating in the blood
is a potential pseudo-target decoy; Betabart has
demonstrated favorable affinity ratio for 4Ig:2Ig in
preclinical models
RADIOPHARM THERANOSTICS LTD 2024
5
BETABART®: 56% Increased Survival with single dose injection
CT26 hB7H3 100uCi90Y-DOTA-MIL33B I.V. (n = 15)
CT26 Vector 100uCi 90Y-DOTA-MIL33B I.V. (n = 9)
100
90
CT26 hB7H3 Saline I.V. (n = 23)
CT26 hB7H3 nothing (n = 20)
70
(* p = 0.0376, log-rank test)
(** p = 0.0034, log-rank test)
(*** p = 0.003, log-rank test)
60
50
*
30
***
40
**
Percent Survival
80
CT26 4lg-B7-H3 Tumors
100 µCi 90Y-DOTA-MIL33B
20
10
0
No Treatment
0
20
40
60
80
100
Days Post Tumor Injection
Preclinical study performed at MD Anderson
RADIOPHARM THERANOSTICS LTD 2024
6
CLINICAL DEVELOPMENT & REGULATORY STRATEGY
•
Preclinical models validated selective targeting of tumor cells
•
Significant tumor reduction and increased survival in animal model
•
GMP CMC production ongoing. GMP batch in Q3 2024
•
GLP TOX and Biodistribution studies in Q3 –Q4 2024
•
Phase I trial in the first half of 2025
Preclinical
PHASE I
Basket trial in multiple indications
CMC GMP, GLP Tox, BioD
25 pts
completed by end 2024
Opening in first half 2025
RADIOPHARM THERANOSTICS LTD 2024
7
RADIOPHARM THERANOSTICS LTD 2024
8
Share your feedback
Discover